AZN Phase 3 readout: a negative outcome, -5.7%

On February 7, 2025, AstraZeneca PLC reached its Phase 3 readout. The result was a negative outcome, and the stock moved -5.7% in the window around the event. It had already run +5.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.